📰 Nasdaq Cbay News
Page 7 - Nasdaq Cbay News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Cbay. Real-time updates on events, politics, business and more.
May 29, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) has been given an average rating of “Buy” by the nine analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. […]
May 27, 2023
StockNews.com upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) from a sell rating to a hold rating in a research report report published on Tuesday morning. A number of other brokerages have also weighed in on CBAY. HC Wainwright raised their target price on shares of CymaBay Therapeutics from $10.00 to $12.00 in a […]
May 27, 2023
StockNews.com upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) from a sell rating to a hold rating in a report issued on Tuesday morning. Several other brokerages have also issued reports on CBAY. Cantor Fitzgerald upped their price target on CymaBay Therapeutics from $13.00 to $15.00 in a research note on Tuesday, May 16th. […]
May 26, 2023
StockNews.com upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) from a sell rating to a hold rating in a research note published on Tuesday morning. CBAY has been the topic of several other reports. Piper Sandler boosted their target price on shares of CymaBay Therapeutics from $12.00 to $19.00 and gave the company an […]
May 22, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating)’s share price dropped 4.6% on Monday after an insider sold shares in the company. The company traded as low as $8.68 and last traded at $8.69. Approximately 786,486 shares traded hands during trading, a decline of 52% from the average daily volume of 1,639,025 shares. The stock had […]
May 20, 2023
CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) had its price objective raised by Cantor Fitzgerald from $13.00 to $15.00 in a report issued on Tuesday morning, The Fly reports. Cantor Fitzgerald also issued estimates for CymaBay Therapeutics’ FY2023 earnings at ($1.15) EPS. A number of other research analysts have also issued reports on CBAY. Raymond James […]
May 19, 2023
StockNews.com cut shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) from a hold rating to a sell rating in a research note published on Monday. CBAY has been the topic of several other research reports. SVB Leerink boosted their target price on shares of CymaBay Therapeutics from $10.00 to $12.00 and gave the stock an […]
May 18, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) General Counsel Paul T. Quinlan sold 5,000 shares of CymaBay Therapeutics stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $10.37, for a total value of $51,850.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, […]
May 18, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) – Analysts at HC Wainwright lifted their Q2 2023 earnings per share estimates for CymaBay Therapeutics in a report released on Tuesday, May 16th. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will post earnings per share of $0.04 for the quarter, up from their […]
May 16, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 11,070,000 shares, a growth of 7.3% from the April 15th total of 10,320,000 shares. Based on an average daily volume of 1,640,000 shares, the days-to-cover ratio is […]